# A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta

Source: https://onco.cc/trials/nct04547166/  
OnCo record `nct04547166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Serplulimab, Bevacizumab in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) is a phase 2/3 interventional study registered as NCT04547166 by Shanghai Henlius Biotech, with 568 participants planned, started 2021-03-10 and due to reach its primary completion in 2025-09-24. Interventions recorded: HLX10, HLX04、. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04547166
- Phase: 2/3
- Setting: A Randomized, Double-blind, Multicenter, PhaseⅡ/Ⅲ Clinical Study of Serplulimab in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 568

## Sources

- ClinicalTrials.gov NCT04547166: https://clinicaltrials.gov/study/NCT04547166

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct04547166.json